Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
OGXI's Cash to Debt is ranked higher than
83% of the 919 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. OGXI: No Debt )
OGXI' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: No Debt

Equity to Asset 0.53
OGXI's Equity to Asset is ranked higher than
65% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. OGXI: 0.53 )
OGXI' s 10-Year Equity to Asset Range
Min: -5.36   Max: 0.95
Current: 0.53

-5.36
0.95
F-Score: 3
Z-Score: -3.44
M-Score: -3.72
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -94.55
OGXI's Operating margin (%) is ranked higher than
69% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. OGXI: -94.55 )
OGXI' s 10-Year Operating margin (%) Range
Min: -48696   Max: 9.64
Current: -94.55

-48696
9.64
Net-margin (%) -92.19
OGXI's Net-margin (%) is ranked higher than
70% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -69.75 vs. OGXI: -92.19 )
OGXI' s 10-Year Net-margin (%) Range
Min: -46544   Max: 10.24
Current: -92.19

-46544
10.24
ROE (%) -85.44
OGXI's ROE (%) is ranked higher than
59% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -28.10 vs. OGXI: -85.44 )
OGXI' s 10-Year ROE (%) Range
Min: -621.05   Max: 12.27
Current: -85.44

-621.05
12.27
ROA (%) -56.58
OGXI's ROA (%) is ranked higher than
59% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. OGXI: -56.58 )
OGXI' s 10-Year ROA (%) Range
Min: -74.08   Max: 7.33
Current: -56.58

-74.08
7.33
ROC (Joel Greenblatt) (%) -5842.89
OGXI's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. OGXI: -5842.89 )
OGXI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -18547.17   Max: 48.05
Current: -5842.89

-18547.17
48.05
Revenue Growth (%) 1.70
OGXI's Revenue Growth (%) is ranked higher than
77% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. OGXI: 1.70 )
OGXI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 628.7
Current: 1.7

0
628.7
EBITDA Growth (%) 4.60
OGXI's EBITDA Growth (%) is ranked higher than
84% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. OGXI: 4.60 )
OGXI' s 10-Year EBITDA Growth (%) Range
Min: -74.3   Max: 104.5
Current: 4.6

-74.3
104.5
EPS Growth (%) 6.60
OGXI's EPS Growth (%) is ranked higher than
85% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. OGXI: 6.60 )
OGXI' s 10-Year EPS Growth (%) Range
Min: -74.7   Max: 96.2
Current: 6.6

-74.7
96.2
» OGXI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

OGXI Guru Trades in Q3 2013

Jim Simons 52,200 sh (+57.7%)
» More
Q4 2013

OGXI Guru Trades in Q4 2013

Jim Simons 84,800 sh (+62.45%)
» More
Q1 2014

OGXI Guru Trades in Q1 2014

Jim Simons 89,522 sh (+5.57%)
» More
Q2 2014

OGXI Guru Trades in Q2 2014

George Soros 30,800 sh (New)
Jean-Marie Eveillard 574,712 sh (New)
Jim Simons 279,922 sh (+212.69%)
» More
» Details

Insider Trades

Latest Guru Trades with OGXI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-06-30 New Buy0.01%$3.35 - $11.5 $ 2.82-50%574712
George Soros 2014-06-30 New Buy$3.35 - $11.5 $ 2.82-50%30800
Jean-Marie Eveillard 2011-06-30 Sold Out $15.29 - $18.64 $ 2.82-83%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.66
OGXI's P/B is ranked higher than
93% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 5.71 vs. OGXI: 1.66 )
OGXI' s 10-Year P/B Range
Min: 0.14   Max: 9
Current: 1.66

0.14
9
P/S 1.18
OGXI's P/S is ranked higher than
98% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 20.23 vs. OGXI: 1.18 )
OGXI' s 10-Year P/S Range
Min: 0.23   Max: 47.95
Current: 1.18

0.23
47.95
EV-to-EBIT -0.05
OGXI's EV-to-EBIT is ranked higher than
76% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. OGXI: -0.05 )
OGXI' s 10-Year EV-to-EBIT Range
Min: 11.1   Max: 15.6
Current: -0.05

11.1
15.6
Current Ratio 2.37
OGXI's Current Ratio is ranked higher than
64% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. OGXI: 2.37 )
OGXI' s 10-Year Current Ratio Range
Min: 0.05   Max: 18.91
Current: 2.37

0.05
18.91
Quick Ratio 2.37
OGXI's Quick Ratio is ranked higher than
66% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. OGXI: 2.37 )
OGXI' s 10-Year Quick Ratio Range
Min: 0.05   Max: 18.91
Current: 2.37

0.05
18.91

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.54
OGXI's Price/Net Cash is ranked higher than
96% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 86.53 vs. OGXI: 2.54 )
OGXI' s 10-Year Price/Net Cash Range
Min: 0.59   Max: 847.67
Current: 2.54

0.59
847.67
Price/Net Current Asset Value 2.09
OGXI's Price/Net Current Asset Value is ranked higher than
97% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 52.38 vs. OGXI: 2.09 )
OGXI' s 10-Year Price/Net Current Asset Value Range
Min: 0.58   Max: 847.67
Current: 2.09

0.58
847.67
Price/Tangible Book 1.66
OGXI's Price/Tangible Book is ranked higher than
95% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. OGXI: 1.66 )
OGXI' s 10-Year Price/Tangible Book Range
Min: 0.47   Max: 30.82
Current: 1.66

0.47
30.82
Price/Median PS Value 0.23
OGXI's Price/Median PS Value is ranked higher than
98% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. OGXI: 0.23 )
OGXI' s 10-Year Price/Median PS Value Range
Min: 0.08   Max: 277.09
Current: 0.23

0.08
277.09
Earnings Yield (Greenblatt) 29.90
OGXI's Earnings Yield (Greenblatt) is ranked higher than
89% of the 472 Companies
in the Global Biotechnology industry.

( Industry Median: 4.90 vs. OGXI: 29.90 )
OGXI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 6.4   Max: 9
Current: 29.9

6.4
9
Forward Rate of Return (Yacktman) -24.94
OGXI's Forward Rate of Return (Yacktman) is ranked higher than
67% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: -10.76 vs. OGXI: -24.94 )
OGXI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -72.5   Max: -58.1
Current: -24.94

-72.5
-58.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:SP4A.Germany
OncoGenex Pharmaceuticals, Inc., a Delaware corporation was incorporated in October 1991. It is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. It has three product candidates in its pipeline, custirsen, OGX-427 and OGX-225, each of which has a distinct mechanism of action and represents a unique opportunity for cancer drug development. Of the product candidates in its pipeline, custirsen and OGX-427 are clinical-stage assets. The Company's product candidate, custirsen, OGX-427, and OGX-225 focus on mechanisms of treatment resistance in cancer patients and are designed to block the production of specific proteins that promote survival of tumor cells and are over-produced in response to a variety of cancer treatments. The Company's aim in targeting these particular proteins is to disable the tumor cell's adaptive defenses, thereby rendering the tumor cells more susceptible to attack with a variety of cancer therapies. Custirsen is its product candidate designed to inhibit the production of clusterin, an antiapoptotic, stress-induced protein which will promote the survival of cancer cells when overexpressed in a variety of tumors. The Company and collaborating investigators have conducted five phase 2 clinical trials to evaluate the ability of custirsen to enhance the effects of therapy in prostate, non-small cell lung and breast cancers. OGX-427 is its product candidate that is designed to inhibit production of heat shock protein 27, or Hsp27, a cell-survival protein expressed in many types of cancers including prostate, bladder, breast and non-small cell lung cancer. Hsp27 expression is stress-induced, including by many anti-cancer therapies. OGX-225 is a product candidate in pre-clinical development that is designed to inhibit production of both Insulin Growth Factor Binding Protein-2, or IGFBP-2, and Insulin Growth Factor Binding Protein-5, or IGFBP-5. Increased IGFBP-2 or IGFBP-5 production is observed in many human cancers, including prostate, non-small cell lung, breast, ovarian, bladder, pancreatic and colon, as well as acute myeloid leukemia, acute lymphoblastic leukemia, neuroblastoma, glioma and melanoma. It faces significant competition from many pharmaceutical, biopharmaceutical and biotechnology companies that are researching and marketing products.
» More Articles for OGXI

Headlines

Articles On GuruFocus.com
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 1 Jan 06 2011 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 5 Dec 03 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 5 Nov 17 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES (OGXI) President and CEO Scott Daniel Cormack sells 5 Nov 02 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) Aug 05 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q/A) May 10 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) May 06 2010 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) Nov 05 2009 
ONCOGENEX PHARMACEUTICALS INC. - COMMON SHARES Reports Operating Results (10-Q) Aug 06 2009 
OncoGenex Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2009 


More From Other Websites
5 Stocks Under $10 to Trade for Breakouts Sep 18 2014
OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in... Sep 16 2014
OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in... Sep 16 2014
4 Under-$10 Biotech Stocks in Breakout Territory Aug 27 2014
OncoGenex's Custirsen Passes First Interim Futility Analysis Aug 22 2014
OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell... Aug 21 2014
OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell... Aug 21 2014
ONCOGENEX PHARMACEUTICALS, INC. Financials Aug 19 2014
OncoGenex Q2 Loss Narrower than Expected, Revenues Down Y/Y Aug 08 2014
OncoGenex Pharmaceuticals (OGXI) Soars: Stock Up 8.2% Aug 08 2014
ONCOGENEX PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Aug 07 2014
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2014 Aug 07 2014
OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2014 Aug 07 2014
Q2 2014 Oncogenex Pharmaceuticals, Inc. Earnings Release - After Market Close Aug 07 2014
OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief... Aug 07 2014
OncoGenex Pharmaceuticals Announces Appointment of John A. Bencich as Vice President and Chief... Aug 07 2014
OncoGenex to Report Financial Results for Second Quarter 2014 on August 7, 2014 Jul 24 2014
OncoGenex to Report Financial Results for Second Quarter 2014 on August 7, 2014 Jul 24 2014
OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in... Jul 01 2014
OncoGenex Announces Cedar™ Clinical Trial Evaluating Apatorsen in Combination with Chemotherapy in... Jul 01 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK